Faeth CFO buys 15,641 shares in open market
Faeth Therapeutics, Inc.’s Chief Financial Officer Brian C. Stephenson reported multiple indirect open-market purchases of the company’s common stock.
Rhea-AI Filing Summary
Faeth Therapeutics, Inc.’s Chief Financial Officer Brian C. Stephenson reported multiple indirect open-market purchases of the company’s common stock. Over June 24 and June 26, 2026, a revocable trust associated with him bought a total of 15,641 shares at prices ranging from about $23.61 to $27.77 per share. Following these transactions, the trust held 33,054 shares of Faeth Therapeutics common stock. The shares are held by the Brian Stephenson Revocable Trust, where he is sole trustee with sole voting and investment power, while he disclaims beneficial ownership except to the extent of his pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 15,641 shares
Net Buy
8 txns
Insider
STEPHENSON BRIAN C
Role
Chief Financial Officer
Bought
15,641 shs ($401K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 580 | $23.61 | $14K |
| Purchase | Common Stock | 4,212 | $24.90 | $105K |
| Purchase | Common Stock | 1,358 | $25.55 | $35K |
| Purchase | Common Stock | 100 | $26.39 | $3K |
| Purchase | Common Stock | 2,891 | $25.22 | $73K |
| Purchase | Common Stock | 3,000 | $25.98 | $78K |
| Purchase | Common Stock | 3,400 | $26.98 | $92K |
| Purchase | Common Stock | 100 | $27.77 | $3K |
Holdings After Transaction:
Common Stock — 33,054 shares (Indirect, See footnote)
Footnotes (7)
- F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.50 to $25.435, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- F2. These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
- F3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.58 to $26.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- F4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.61 to $27.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- F5. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.27 to $24.1663, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- F6. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.27 to $25.2405, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- F7. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.335 to $26.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Key Figures
Total shares purchased: 15,641 shares
Post-transaction holdings: 33,054 shares
Highest reported price: $27.77 per share
+3 more
6 metrics
Total shares purchased
15,641 shares
Net open-market buys reported in Form 4
Post-transaction holdings
33,054 shares
Indirect common stock held by revocable trust
Highest reported price
$27.77 per share
Individual open-market purchase price on June 24, 2026
Lowest reported price
$23.61 per share
Individual open-market purchase price on June 26, 2026
Number of buy transactions
8 transactions
Non-derivative open-market purchases of common stock
Transaction dates
June 24 and 26, 2026
Dates of reported open-market purchases
Key Terms
open-market purchase, weighted average price, Revocable Trust, beneficial ownership, +1 more
5 terms
open-market purchase financial
"transaction_action: "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Revocable Trust financial
"These shares are held directly by the Brian Stephenson Revocable Trust"
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
beneficial ownership financial
"The Reporting Person disclaims beneficial ownership of the shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"except to the extent of his pecuniary interest therein."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did Faeth Therapeutics (FTH) disclose in this Form 4?
Faeth Therapeutics disclosed that its Chief Financial Officer, Brian C. Stephenson, reported indirect open-market purchases of common stock through a revocable trust on June 24 and June 26, 2026, increasing that trust’s holdings to 33,054 shares after the reported transactions.
What is the CFO’s reported indirect ownership in Faeth Therapeutics (FTH) after these trades?
After the reported open-market purchases, the Brian Stephenson Revocable Trust held 33,054 shares of Faeth Therapeutics common stock indirectly attributable to CFO Brian Stephenson, as shown in the post-transaction ownership column of the Form 4 transaction table for these non-derivative securities.
Were any derivatives or options reported in this Faeth Therapeutics (FTH) Form 4?
No derivative securities were listed in the derivative section for this Form 4. All reported transactions involved non-derivative Faeth Therapeutics common stock, and the derivativeSummary section for the filing was empty, indicating no options or similar instruments in this particular report.
How many separate open-market trades did the Faeth Therapeutics (FTH) CFO report?
The filing shows eight separate open-market purchase transactions in Faeth Therapeutics common stock. These trades occurred on June 24 and June 26, 2026, with each line item reflecting a specific share amount and weighted average price for that portion of the overall buying activity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
